Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00952523 · ClinicalTrials.gov registry record · Phase 4

Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face

A Phase 4 study of Acne Vulgaris, sponsored by Bausch Health Americas.

Completed
Registry status
Phase 4
Development phase
162
Enrollment target
1
Study location

NCT00952523: Completed Phase 4 study of Acne Vulgaris, sponsored by Bausch Health Americas.

NCT00952523 is a Phase 4 study of Acne Vulgaris that has completed, run by Bausch Health Americas. The registered enrollment target is 162 participants, below the 273-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00952523, a Phase 4 study of Acne Vulgaris, has completed, sponsored by Bausch Health Americas.

COMPLETED
Registry status
Phase 4
Development phase
162 participants
Enrollment target
1
Study location

Study Summary

A study to compare the skin irritation potential of two marketed gels for acne treatment, each applied to half of the face of healthy volunteers.

Primary Outcome

Scores on a scale were recorded each weekday. The scale for Erythema and Dryness was from 0=none to 8=severe (highest possible score is calculated as 8x5daysx3weeks=120). The scale for Burning/Stinging and Itching was from 0=none to 3=severe (highest possible score was calculated as 3x5daysx3weeks=45). The scores that were accumulated through the study for each treatment were then compared.

Conditions Studied

Interventions

  • DRUG Tretinoin Facial Gel
  • DRUG Adapalene/Benzoyl Peroxide Facial Gel

Study Locations (1)

Pennsylvania

  • Skin Study Center - Broomall

Trial Details

FieldValue
Enrollment Target 162 participants
Start Date 2009-07
Est. Completion 2009-10
Phase Phase 4
Bausch Health Americas

168 total trials

What the finished NCT00952523 record still lists

NCT00952523 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, below the 273-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (41% lower).

The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Tretinoin Facial Gel is the first listed.

NCT00952523 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00952523 about?

NCT00952523 is a clinical study titled "Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face". A study to compare the skin irritation potential of two marketed gels for acne treatment, each applied to half of the face of healthy volunteers.

What is the current status of trial NCT00952523?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 162 participants. The study started on 2009-07. Estimated completion is 2009-10.

What conditions does trial NCT00952523 study?

This clinical trial studies the following conditions: Acne Vulgaris.

What interventions are being tested in trial NCT00952523?

The interventions under investigation include: Tretinoin Facial Gel (DRUG), Adapalene/Benzoyl Peroxide Facial Gel (DRUG).

Who is sponsoring clinical trial NCT00952523?

This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00952523 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acne Vulgaris

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00952523's enrollment target sits among peer trials

162 32nd of 67 higher than 36 of 67 other Acne Vulgaris trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02347111 · 162 participants · Phase 4

    Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

  • NCT02610426 · 162 participants

    Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

  • NCT05040711 · 162 participants · NA

    mHealth Mindfulness With Patients With Serious Illness and Their Caregivers

  • NCT05514717 · 162 participants · Phase 1

    A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00952523, the US trial registry maintained by the National Library of Medicine. NCT00952523 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.